Cardiac, Neuropsychiatric Events With ADHD Drugs To Be Discussed By Pediatric Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Pediatric Advisory Committee will address neuropsychiatric and cardiovascular events possibly related to attention deficit/hyperactivity disorder medications at a March 22 meeting